ARMP

Armata Pharmaceuticals, Inc.

2.39 USD

Last updated Dec 6, 00:42 UTC

Yesterday HIGH

$2.8

Yesterday LOW

$2.07

52w HIGH

$5.26

52w LOW

$0.83

EPS

-0.86

PE

-2.78

Next Earnings

Mar 14, 2024

Overview News Government Trades

Armata Pharmaceuticals, Inc. stock is up 3.91% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.67% of the previous 29 December’s closed higher than November.

Armata Pharmaceuticals, Inc. focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PS03 for pneumonia.

Stock Exchange

NYSE MKT

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Marina Del Rey, United States Of America

Website

armatapharma.com

Benzinga Insights

Mon May 8, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
richadhand@benzinga.com

Fri Mar 17, 2023

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 price target.
Bill Haddad

Thu Mar 16, 2023

Armata Pharmaceuticals Q4 EPS $(0.29) Misses $(0.28) Estimate

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.28) by 3.57 percent. This is a 26.09 percent decrease over losses of $(0.23) per share
richadhand@benzinga.com

Tue Mar 7, 2023

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 price target.
Lisa Levin

Mon Mar 6, 2023

Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb.
Vandana Singh

Mon Mar 6, 2023

Investors Cheer Armata Pharma's Encouraging Data From Lung Infection Candidate
Benzinga Insights

Mon Mar 6, 2023

12 Health Care Stocks Moving In Monday's Pre-Market Session
Charles Gross

Mon Mar 6, 2023

Armata Pharmaceuticals Announced Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Armata Pharmaceuticals, Inc. (NYSE: ARMP) , today announced positive topline results from the completed Phase 1b/2a SWARM-P.a. trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients.
Lisa Levin

Tue Jan 24, 2023

Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in patients undergoing elective surgery.
Lisa Levin

Wed Jan 4, 2023

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.